down arrow

Prime Medicine, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74168J1016
USD
3.85
0.55 (16.67%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.584.08

52 Week

1.116.94
Valuation
Technical
Day's Volume

CASH

6.22 M

Shareholding (Mar 2025)

FII

7.73%

Held by 48 FIIs

DII

61.49%

Held by 22 DIIs

Promoter

16.69%

How big is Prime Medicine, Inc.?

22-Jun-2025

As of Jun 18, Prime Medicine, Inc. has a market capitalization of 212.04 million, with net sales of 3.84 million and a net profit of -202.02 million over the last four quarters. Shareholder's funds are 153.15 million, and total assets are 490.14 million.

As of Jun 18, Prime Medicine, Inc. has a market capitalization of 212.04 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 3.84 million, while the sum of net profit for the same period is -202.02 million.<BR><BR>As of Dec 24, the shareholder's funds amount to 153.15 million, and total assets are reported at 490.14 million.

Read More

What does Prime Medicine, Inc. do?

22-Jun-2025

Prime Medicine, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $52 million as of March 2025. It has a market cap of $212.04 million and key metrics indicating significant financial challenges.

Overview:<BR>Prime Medicine, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -52 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 212.04 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.29 <BR>Return on Equity: -186.40% <BR>Price to Book: 1.98<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is Prime Medicine, Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Prime Medicine, Inc. shows a mildly bullish trend with mixed technical indicators, including bullish moving averages and MACD, but bearish RSI readings, while outperforming the S&P 500 significantly over the past month and year-to-date.

As of 10 October 2025, the technical trend for Prime Medicine, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. However, the RSI readings are bearish for both weekly and monthly periods. The Bollinger Bands indicate a mildly bullish stance weekly and bullish monthly. Moving averages are bullish on a daily basis, while the Dow Theory shows a mildly bullish trend in both weekly and monthly time frames. The OBV is mildly bullish weekly but mildly bearish monthly. <BR><BR>In terms of performance, the stock has returned 38.82% over the past month compared to a mere 0.31% for the S&P 500, and it has a year-to-date return of 93.49% against the S&P 500's 11.41%. Overall, the current technical stance is mildly bullish, driven by the mixed indicators across different time frames.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Positive results in Jun 25

  • NET SALES(HY) At USD 2.57 MM has Grown at 334.69%
  • OPERATING CASH FLOW(Y) Highest at USD -99.94 MM
  • NET PROFIT(HY) Higher at USD -102.92 MM
2

Risky - Negative EBITDA

3

High Institutional Holdings at 52.15%

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 693 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.55

stock-summary
Return on Equity

-325.32%

stock-summary
Price to Book

11.39

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-53 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.27%
0%
15.27%
6 Months
189.47%
0%
189.47%
1 Year
23.0%
0%
23.0%
2 Years
-52.23%
0%
-52.23%
3 Years
-77.85%
0%
-77.85%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Prime Medicine, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Prime Medicine Stock Hits Day Low of $4.45 Amid Price Pressure

Prime Medicine Stock Hits Day Low of $4.45 Amid Price Pressure

Prime Medicine, Inc. has faced a significant stock decline, with a notable drop in both weekly and monthly performance. Despite reporting substantial growth in net sales, the company struggles with negative EBITDA and high operating cash flow losses. Its long-term performance reflects considerable volatility in the market.

Read More
Prime Medicine, Inc. Experiences Evaluation Revision Amidst Strong Market Performance

Prime Medicine, Inc. Experiences Evaluation Revision Amidst Strong Market Performance

Prime Medicine, Inc., a small-cap pharmaceutical company, has recently adjusted its evaluation amid market dynamics. The stock is currently priced at $5.65, with a notable annual return of 55.22%. Technical indicators show a mixed outlook, reflecting the company's volatility and resilience in a competitive sector.

Read More

Is Prime Medicine, Inc. technically bullish or bearish?

As of 10 October 2025, the technical trend for Prime Medicine, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. However, the RSI readings are bearish for both weekly and monthly periods. The Bollinger Bands indicate a mildly bullish stance weekly and bullish monthly. Moving averages are bullish on a daily basis, while the Dow Theory shows a mildly bullish trend in both weekly and monthly time frames. The OBV is mildly bullish weekly but mildly bearish monthly. In terms of performance, the stock has returned 38.82% over the past month compared to a mere 0.31% for the S&P 500, and it has a year-to-date return of 93.49% against the S&P 500's 11.41%. Overall, the current technical stance is mildly bullish, driven by the mixed indicators across different time frames....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
81.31%
EBIT Growth (5y)
-36.99%
EBIT to Interest (avg)
-162.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.29
Sales to Capital Employed (avg)
0.02
Tax Ratio
0.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
52.15%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.08
EV to EBIT
-0.41
EV to EBITDA
-0.42
EV to Capital Employed
-2.77
EV to Sales
21.97
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-186.40%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 38 Schemes (14.06%)

Foreign Institutions

Held by 48 Foreign Institutions (7.73%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 4.88% vs -30.42% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-51.50",
          "val2": "-54.10",
          "chgp": "4.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "-1.90",
          "chgp": "73.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-52.60",
          "val2": "-55.30",
          "chgp": "4.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-47,871.70%",
          "val2": "0.00%",
          "chgp": "-4,787.17%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1.11% vs -62.64% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-196.30",
          "val2": "-186.60",
          "chgp": "-5.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "-15.90",
          "chgp": "96.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-195.90",
          "val2": "-198.10",
          "chgp": "1.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-67,873.60%",
          "val2": "0.00%",
          "chgp": "-6,787.36%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
1.10
0.00
Operating Profit (PBDIT) excl Other Income
-51.50
-54.10
4.81%
Interest
0.00
0.00
Exceptional Items
-0.50
-1.90
73.68%
Consolidate Net Profit
-52.60
-55.30
4.88%
Operating Profit Margin (Excl OI)
-47,871.70%
0.00%
-4,787.17%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 4.88% vs -30.42% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
3.00
0.00
Operating Profit (PBDIT) excl Other Income
-196.30
-186.60
-5.20%
Interest
0.00
0.00
Exceptional Items
-0.50
-15.90
96.86%
Consolidate Net Profit
-195.90
-198.10
1.11%
Operating Profit Margin (Excl OI)
-67,873.60%
0.00%
-6,787.36%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 1.11% vs -62.64% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Prime Medicine, Inc. stock-summary
stock-summary
Prime Medicine, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."